Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER)2/(neu) protein expression in breast cancer drill biopsies

International Journal of Cancer

Volumn 83, Issue 2, 1999, Pages 157-161

  De Cremoux, Patricia ^a,b   Martin, Emmanuel C ^a   Vincent Salomon, Anne ^a   Dieras, Véronique ^a   Barbaroux, Catherine ^a   Liva, Stéphane ^a   Pouillart, Pierre ^a   Sastre Garau, Xavier ^a   Magdelenat, Henri ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST BIOPSY; BREAST CANCER; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DNA, NEOPLASM; DOXORUBICIN; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; PACLITAXEL; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TAXOIDS;

EID: 0032850917     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991008)83:2<157::AID-IJC2>3.0.CO;2-L     Document Type: Article

References (23)

1. ALLRED, D.C., CLARK, G.M., TANDON, A.K., MOLINA, R., TORNEY, D.C., OSBORNE, C.K., GILCHRIST, K.W., MANSOUR, E.G., ABELOFF, M., EUDEY, L. and MCGUIRE, W.L., HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. clin. Oncol., 10, 599-605 (1992).
2. ANDRULIS, I.L. AND 22 OTHERS, Neu/erbB-2 amplification identifies a poor-prognosis group of women with node negative breast cancer. Toronto Breast Cancer Study Group. J. clin Oncol., 16, 1340-1349 (1998).
3. ARCHER, S.G., ELIOPOULOS, A., SPANDIDOS, D., BARNES, D., ELLIS, I.O., BLAMEY, R.W., NICHOLSON, R.J. and ROBERTSON, J.F., Expression of ras, p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Brit. J. Cancer, 72, 1259-1266 (1995).
4. BECKER-ANDRE, M. and HAHLBROCK, K., Absolute mRNA quantification using the polymerase chain reaction. A novel approach by a PCR aided transcription assay (PATTY). Nucleic Acids Res., 17, 9437-9446 (1989).
5. CELI, F.S., COHEN, M.M., ANTONARAKIS, S.E., WERTHEIMER, E., ROTH, J. and SHULDINER, A.R., Determination of gene dosage by a quantitative adaptation of the polymerase chain reaction (gd-PCR): rapid detection of deletion and duplications of gene sequences. Genomics, 21, 304-310 (1994).
6. CLARK, G.M., Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J. nat. Cancer Inst., 90, 1320-1321 (1998).
7. FISCHER, B. AND 13 OTHERS, Effect of preoperative chemotherapy on locoregional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J. clin. Oncol., 15, 2483-2493 (1997).
8. FISCHER, B. AND 15 OTHERS, Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. clin. Oncol., 16, 2672-2685 (1998).
9. GUERIN, M., BARROIS, M., TERRIER, M.J., SPIELMAN M. and RIOU, G., Overexpression of either c-myc or c-erbB-2:neu proto-oncogene in human breast carcinomas: correlation with poor prognosis. Oncogene Res., 3, 21-31 (1988).
10. GUSTERSON, B.A. AND 20 OTHERS, for the International Breast Cancer Study Group, Prognostic importance of c-erbB-2 expression in breast cancer. J. clin. Oncol., 10, 1049-1056 (1992).
11. KALLIONIEMI, A., KALLIONIEMI, O.P., PIPER, J., TANNER, M., STOKKES, T., CHEN, L., SMITH, H.S., PINKEL, D., GRAY, J.W. and WALDMAN, F.M., Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridisation. Proc. nat. Acad. Sci. (Wash.), 91, 2156-2160 (1994).
12. KALLIONIEMI, O.P., KALLIONIEMI, A., KURISU, W., THOR, A., CHEN, L.C., SMITH, H.S., WALDMAN, F.M., PINKEL, D. and GRAY, G.W., erbB-2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. nat. Acad. Sci. (Wash.), 89, 5321-5325 (1992).
13. PAIK, S., BRYANT, J., PARK, C., FISHER, B., TAN-CHIU, E., HYAMS, D., FISHER, E.R., LIPMAN, M.E., WICKERHAM, D.L. and WOLMARK, N., erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone-receptor negative breast cancer. J nat. Cancer Inst., 90, 1361-1370 (1998).
14. PIFFANELLI, A., DITTADI, R., CATOZZI, L., GION, M., CAPITANIO, G., GELLI, M.C., BRAZZALE, A., MALAGUTTI, R., PELIZZOLA, D., MENEGON, A., GIOVANNINI, G. and GARDINI, G., Determination of erbB-2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res. Treat., 37, 267-276 (1996).
15. PORCHER, C., MALINGE, M.C., PICAT, C. and GRANDCHAMP, B., A simplified method for determination of specific DNA or RNA copy number using quantitative PCR and an automatic DNA sequencer. Biotechniques, 13, 106-113 (1992).
16. PRESS, M.F. AND 14 OTHERS, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. clin. Oncol., 15, 2894-2904 (1997).
17. REVILLON, F., BONNETERRE, J. and PEYRAT, J.P., ERBB2 oncogene in human breast cancer and its clinical significance. Europ. J. Cancer, 34, 791-808 (1998).
18. ROZAN, S., VINCENT-SALOMON, A., ZAFRANI, B., VALIDIRE, P., DE CREMOUX, P., BERNOUX, A., NIERUCHALSKI, M., FOURQUET, A., CLOUGH, K, DIERAS, V., POUILLART, P. and SASTRE-GARAU, X., No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer, 79, 27-33 (1998).
19. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. and MCGUIRE, W.L., Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science, 235, 177-182 (1987).
20. TANDON, A.K., CLARK, G.M., CHAMNESS, G.C., ULLRICH, A. and MCGUIRE, W.L., HER2/neu oncogene protein and prognosis in breast cancer, J. clin. Oncol., 7, 1120-1128 (1989).
21. THOR, A.D., BERRY, D.A., BUDMAN, D.R., MUSS, H.B., KUTE, T., HENDERSON, I.C., BARCOS, M., CIRRINCIONE, C., EDGERTON, S., ALLRED, C., NORTON, L. and LIU, E.T., erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. nat. Cancer Inst., 90, 1346-1360 (1998).
22. VALERON, P.F., CHIRINO, R., FERNANDEZ, L., TORRES, S., NAVARRO, D., AGUIAR, J., CABRERA, J.J., DIAZ-CHICO, N. and DIAZ-CHICO, J.C., Validation of a differential PCR and ELISA procedure in studying HER2:neu status in breast cancer. Int. J. Cancer, 65, 129-133 (1996).
23. WRIGHT, C., NICHOLSON, S., ANGUS, B., SAINSBURY, J.R.C., FARNDON, J., CAIRNS, J., HARRIS, A.L. and HORNE, C.H.W., Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advance breast cancer. Brit. J. Cancer, 65, 118-121 (1992).